Table 3.
Adverse events contributing to regimen adjustment, interruption, or discontinuation
| Alectinib | Crizotinib | |||||||
|---|---|---|---|---|---|---|---|---|
| sAE | Dose adjustment | Regimen interruption | Treatment discontinuation | sAE | Dose adjustment | Regimen interruption | Treatment discontinuation | |
| N | 23 | 19 | 16 | 2 | 9 | 10 | 5 | 5 |
| Rash | 1 (4.3) | 3 (15.8) | 4 (25.0) | 1 (11.1) | 1 (10.0) | 1 (20.0) | ||
| Liver toxicity | 2 (8.7) | 2 (10.5) | 1 (6.2) | 1 (50.0) | 1 (11.1) | 2 (20.0) | 3 (60.0) | 4 (80.0) |
| Bradycardia | 4 (20.1) | 1 (6.2) | 2 (20.0) | 1 (20.0) | ||||
| Pneumonia | 2 (8.7) | 1 (5.3) | 2 (12.5) | 2 (22.2) | 1 (20.0) | |||
| Fatigue | 3 (15.8) | 1 (6.2) | 2 (20.0) | 1 (20.0) | ||||
| Pulmonary embolism | 2 (8.7) | 3 (33.3) | 1 (10.0) | |||||
| Nausea | 1 (4.3) | 1 (50.0) | 1 (11.1) | 1 (10.0) | 1 (20.0) | |||
| Blood bilirubin increased | 1 (4.3) | 2 (10.5) | 2 (12.5) | |||||
| Fever | 1 (5.3) | 2 (12.5) | 1 (11.1) | 1 (20.0) | ||||
| Pericardial effusion | 4 (17.4) | 1 (11.1) | ||||||
| Pleural effusion | 4 (17.4) | 1 (20.0) | ||||||
| Diarrhea | 1 (4.3) | 1 (6.2) | 2 (20.0) | |||||
| Constipation | 1 (4.3) | 2 (10.5) | 2 (12.5) | |||||
| Vomiting | 1 (4.3) | 1 (50.0) | 1 (11.1) | 2 (20.0) | ||||
| Pyelonephritis | 2 (8.7) | 1 (5.3) | 1 (6.2) | |||||
| Hematoma NOS | 2 (8.7) | 1 (6.2) | 1 (11.1) | |||||
| Sepsis | 2 (8.7) | 1 (6.2) | ||||||
| Diabetic ketoacidosis | 1 (4.3) | 1 (5.3) | 1 (6.2) | |||||
| Edema peripheral | 1 (5.3) | 1 (10.0) | 1 (20.0) | |||||
| Hyponatremia | 2 (8.7) | 1 (5.3) | ||||||
| Swelling face | 1 (5.3) | 1 (6.2) | 1 (20.0) | |||||
| Muscle weakness NOS | 1 (5.3) | 1 (6.2) | ||||||
| Deep vein thrombosis | 1 (4.3) | 1 (11.1) | ||||||
| Face edema | 1 (5.3) | 1 (6.2) | ||||||
| Anemia | 2 (10.5) | |||||||
| Mouth ulceration | 1 (5.3) | 1 (6.2) | ||||||
| Dysphagia | 1 (11.1) | 1 (10.0) | ||||||
| Ileus paralytic | 1 (4.3) | 1 (6.2) | ||||||
| Renal abscess NOS | 1 (5.3) | 1 (6.2) | ||||||
| Pain | 1 (4.3) | 1 (11.1) | ||||||
| Shingles | 1 (4.3) | 1 (6.2) | ||||||
| Cardiac failure | 1 (4.3) | 1 (11.1) | ||||||
| Gastrointestinal toxicity | 1 (4.3) | 1 (10.0) | ||||||
| Pancytopenia | 1 (11.1) | 1 (20.0) | ||||||
| Urinary tract infection | 1 (4.3) | 1 (5.3) | ||||||
| CK increased | 1 (5.3) | 1 (6.2) | ||||||
| Drug toxicity | 1 (5.3) | |||||||
| Neutrophil count decreased | 1 (20.0) | |||||||
| Serum ferritin increased | 1 (20.0) | |||||||
| Drug intolerance | 1 (5.3) | |||||||
| Acute generalized exanthematous pustulosis | 1 (6.2) | |||||||
| Chills | 1 (6.2) | |||||||
| Dizziness | 1 (5.3) | |||||||
| Muscle spasms | 1 (6.2) | |||||||
| Pulmonary edema | 1 (20.0) | |||||||
| Chylous ascites | 1 (10.0) | |||||||
| Q-T interval prolonged | 1 (20.0) | |||||||
| Alopecia | 1 (11.1) | |||||||
| Leukopenia | 1 (5.3) | |||||||
| Decreased appetite | 1 (10.0) | |||||||
| Insomnia | 1 (10.0) | |||||||
| Bacteremia | 1 (4.3) | |||||||
| Acute kidney injury | 1 (4.3) | 1 (6.2) | ||||||
| Acute myocardial infarction | 1 (11.1) | |||||||
| Encephalopathy | 1 (4.3) | |||||||
| Libido decreased | 1 (20.0) | |||||||
CK creatine kinase, NOS not otherwise specified